ScholarIQanswers from OpenAlex & ORCID
Sara M. Tolaney
ResearcherPublications, citations & collaboration network
Sara M. Tolaney is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Sara M. Tolaney have?
ScholarIQindexed works
Sara M. Tolaney has 1,340 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sara M. Tolaney have?
ScholarIQcitation count
Sara M. Tolaney has 38,942 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Sara M. Tolaney?
ScholarIQh-index
Sara M. Tolaney has an h-index of 86 in OpenAlex.
What is the i10-index of Sara M. Tolaney?
ScholarIQi10-index
Sara M. Tolaney has an i10-index of 362 in OpenAlex.
What is the ORCID of Sara M. Tolaney?
ScholarIQorcid
The ORCID for Sara M. Tolaney is on the source record.
What is the OpenAlex record for Sara M. Tolaney?
ScholarIQopenalex
The OpenAlex for Sara M. Tolaney is on the source record.
What are the most-cited papers on Sara M. Tolaney?
ScholarIQmost cited works
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Alessandra Gennari, Fabrice André, Carlos H. Barrios, Javier Cortés, Evandro de Azambuja, A. DeMichele, Rebecca Dent, Deborah Fenlon, Joseph Gligorov, Sara A. Hurvitz, Seock‐Ah Im, David Krug, Wolfgang G. Kunz, Sherene Loi, Frédérique Penault‐Llorca, Jens Ricke, Mark E. Robson, Hope S. Rugo, Cristina Saura, Peter Schmid, Christian F. Singer, Tanja Španić, Sara M. Tolaney, Nicholas C. Turner, Giuseppe Curigliano, Sibylle Loibl, Shani Paluch–Shimon, Nadia Harbeck
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
William M. Sikov, Donald A. Berry, Charles M. Perou, Baljit Singh, Constance Cirrincione, Sara M. Tolaney, Charles Kuzma, Timothy Pluard, George Somlo, Elisa Port, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen Hahn, Lisa A. Carey, Clifford A. Hudis, Eric P. Winer
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Mingzhao Xing, William H. Westra, Ralph P. Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J. Rhoden, Kathryn A. Carson, Vasily Vasko, О. С. Ларін, Giovanni Tallini, Sara M. Tolaney, Elizabeth H. Holt, Pei Hui, Christopher B. Umbricht, Shehzad Basaria, Marge Ewertz, Anthony P. Tufaro, Joseph A. Califano, Matthew D. Ringel, Martha A. Zeiger, David Sidransky, Paul W. Ladenson
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan, Robert Iannone, Sarah A. Washkowitz, Robert M. Sharkey, William A. Wegener, Kevin Kalinsky